Literature DB >> 34596055

Propranolol inhibits cavernous vascular malformations by β1 adrenergic receptor antagonism in animal models.

Wenqing Li, Robert Shenkar, Mathew R Detter, Thomas Moore, Christian Benavides, Rhonda Lightle, Romuald Girard, Nicholas Hobson, Ying Cao, Yan Li, Erin Griffin, Carol Gallione, Joseph M Zabramski, Mark H Ginsberg, Douglas A Marchuk, Issam A Awad.   

Abstract

Entities:  

Year:  2021        PMID： 34596055      PMCID： PMC8483741          DOI： 10.1172/JCI154909

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   19.456


× No keyword cloud information.
  4 in total

Review 1.  Rapamycin in Cerebral Cavernous Malformations: What Doses to Test in Mice and Humans.

Authors:  Matthew J Hagan; Robert Shenkar; Abhinav Srinath; Sharbel G Romanos; Agnieszka Stadnik; Mark L Kahn; Douglas A Marchuk; Romuald Girard; Issam A Awad
Journal:  ACS Pharmacol Transl Sci       Date:  2022-04-25

Review 2.  Cerebral Cavernous Malformation Pathogenesis: Investigating Lesion Formation and Progression with Animal Models.

Authors:  Chelsea M Phillips; Svetlana M Stamatovic; Richard F Keep; Anuska V Andjelkovic
Journal:  Int J Mol Sci       Date:  2022-04-30       Impact factor: 6.208

Review 3.  The Role of Propranolol as a Repurposed Drug in Rare Vascular Diseases.

Authors:  Angel M Cuesta; Eunate Gallardo-Vara; Juan Casado-Vela; Lucía Recio-Poveda; Luisa-María Botella; Virginia Albiñana
Journal:  Int J Mol Sci       Date:  2022-04-11       Impact factor: 6.208

4.  A murine model of cerebral cavernous malformations with acute hemorrhage.

Authors:  Claudio Maderna; Federica Pisati; Claudio Tripodo; Elisabetta Dejana; Matteo Malinverno
Journal:  iScience       Date:  2022-02-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.